Phase II trial of neoadjuvant and adjuvant capmatinib in participants with stages IB-IIIA, N2 and selected IIIB (T3N2 or T4N2) NSCLC with MET exon 14 skipping mutation or high MET amplification Geometry-N
Study of Capmatinib for Patients with Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Novartis
Enrolling: Male and Female Patients
IRB Number: AAAT8011
U.S. Govt. ID: NCT04926831
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to find out if a drug called capmatinib is safe and effective (can help people) in people who have non-small cell lung cancer (NSCLC) who are also eligible for surgery. Capmatinib is an oral drug that targets particular processes, which may not be working properly in the cancer cells (dysregulation) in the body. Prior to surgery, participants will receive two cycles (a treatment cycle is 4 weeks long) of capmatinib. After the two cycles are complete, participants will undergo surgery to remove their cancer. After surgery, the Study Doctor may or may not prescribe chemotherapy before starting capmatinib treatment again.
Investigator
Catherine Shu, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with non-small cell lung cancer (NSCLC) and it's able to be removed by surgery? Yes No
Are you willing to follow the scheduled study visits, treatment plans, and have extra laboratory tests? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162